Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methylprednisolone Plus Cyclophosphamide in Thyroid Associated Ophthalmopathy
ChiCTR-IPR-17010472Phase 4Recruiting
- Sponsor
- Shanghai Changzheng Hospital
- Start
- Jan 2017
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in Graves Orbitopathy (GO) comparing Cyclophosphamide + methylprednisolone with Methylprednisolone (2 arms). Primary endpoints: Response and Hemorrhagic cystitis. Started Jan 2017; status: recruiting.
02
Drugs
cyclophosphamidemethylprednisolone
03
Conditions
Graves Orbitopathy (GO)
Beyond the preview
Go deeper on ChiCTR-IPR-17010472.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-17010472.